Form 4: Raphael Pharmaceutical Inc. Insider Transaction

Raphael Pharmaceutical Inc. Chief Technology Officer, Hayon Igal Louria, exercised warrants to acquire 350,000 shares of common stock.

Summary

• Hayon Igal Louria, Chief Technology Officer of Raphael Pharmaceutical Inc., engaged in a transaction on November 20, 2025.
• The transaction involved the exercise of warrants to purchase 350,000 shares of common stock at an exercise price of $0.01 per share.
• Following this transaction, Louria beneficially owns 1,349,000 shares of common stock.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as a neutral filing. While an insider exercising warrants can be a positive signal, it is a routine transaction and does not provide new information about the company's financial performance or strategic direction.

Positives

• Insider exercising warrants suggests confidence in the company's future prospects.
• Acquisition of 350,000 shares at a low exercise price of $0.01 per share.

Negatives

• The filing details a transaction by an insider, not a company performance update, so direct financial negatives are not applicable.

Risks

• The filing does not explicitly mention any risks.

Future Outlook

The filing does not contain forward-looking statements or guidance.

Industry Context

StockSavvy.ai notes that Form 4 filings are standard disclosures for insider transactions, providing transparency into the holdings and activities of company executives and major shareholders. This specific filing indicates an insider increasing their stake through warrant exercise, which can sometimes be interpreted as a positive signal by the market.

Comparison to Industry Standards

• This filing is a standard SEC Form 4, which is a regulatory requirement for reporting changes in beneficial ownership by insiders. All publicly traded companies in the US are subject to these reporting standards.

Stakeholder Impact

• Shareholders: May view the insider's warrant exercise as a sign of confidence, potentially influencing investment decisions.
• Employees: The transaction itself has no direct impact on employees, but insider confidence can indirectly affect morale.
• Creditors: No direct impact from this type of transaction.

Next Steps

• Continued monitoring of insider transactions and SEC filings for Raphael Pharmaceutical Inc.

Key Dates

Keywords

Form 4, SEC Filing, Insider Transaction, Beneficial Ownership, Raphael Pharmaceutical Inc., Warrant Exercise, Common Stock, Hayon Igal Louria, Chief Technology Officer